Company Overview and News

 
Godrej Consumer Products eyes Rs 100-crore revenue from male grooming segment

2018-09-18 moneycontrol
Homegrown FMCG firm Godrej Consumer Products (GCPL) is looking to garner revenue worth Rs 100 crore from the male grooming segment over the next two to three years, a top company official said.
GDRJY GODREJCP 532424

 
Godrej Consumer Products gains 3% after board approves bonus share allotment

2018-09-18 moneycontrol
Shares of Godrej Consumer Products added nearly 3 percent intraday Tuesday after company board approved allotment of bonus equity shares.
GDRJY GODREJCP 532424

 
Godrej Consumer Products Limited - Allotment of Securities

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GDRJY GODREJCP 532424

 
Godrej Consumer Products Limited - Shareholders meeting

2018-09-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GDRJY GODREJCP 532424

 
Godrej Consumer hits 52-week high on sell of UK business

2018-09-03 moneycontrol
Share price of Godrej Consumer Products touched 52-week high of Rs 1,469, rising 1.5 percent intraday Monday as company divested entire stake in its UK business.
GDRJY GODREJCP 532424

 
Godrej Consumer Products Limited - Diversification/Disinvestment

2018-08-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GDRJY GODREJCP 532424

 
GCPL sells UK biz to JZ International for over Rs 310 cr

2018-08-31 moneycontrol
Godrej Consumer Products Ltd (GCPL) today said it has divested its entire stake in its UK business, Godrej Consumer Products UK Ltd, to JZ International effective immediately for GBP 34 million (over Rs 310 crore).
GDRJY GODREJCP 532424

 
Godrej Consumer Products Limited - Record Date

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GDRJY GODREJCP 532424

 
Marico expects premium brands biz to double in 3-4 years

2018-08-26 livemint
Mumbai: Marico Ltd has over the past year created a differentiated portfolio and strategy for distribution, sales and marketing of niche premium and mass brands, said a senior company executive. The shift in strategy comes even as the company languishes in its core business of selling Saffola and Parachute oils amid intense competition.
GDRJY EQMNY 500096 DABUR 500696 HINDUNILVR GODREJCP DBRQY 532424

3
PM Modi, Priyanka Chopra, Binny Bansal in LinkedIn most viewed profiles list

2018-08-23 livemint
Professional networking site LinkedIn has released the list of most viewed professionals on its platform for 2017-18. The list includes Prime Minister Narendra Modi, actor Priyanka Chopra, Biocon chief Kiran Mazumdar-Shaw, Paytm founder Vijay Shekhar Sharma and Flipkart founder Binny Bansal.
GDRJY 500696 TCHQY HINDUNILVR GODREJCP 532755 LNKD 532424 TECHM

 
India Inc finds pricing power in fastest-growing world economy

2018-08-23 livemint
From Mercedes-Benz AG to Hindustan Unilever, companies in India are finding power to pass on higher costs to consumers, a sign that demand in the world’s fastest-growing major economy is well-entrenched. After the twin shocks of a cash ban in 2016 and the chaotic introduction of a consumption tax last year, India’s economic recovery is gaining momentum. Businesses are taking advantage of the solid demand to raise prices, lifting profits, but also fanning inflation at a time of higher oil prices and a currency slump.
INDIGO 500228 DABUR HINDUNILVR DBRQY MRZUY AKLD 532424 JSWSTEEL 539448 532500 GDRJY 500470 500096 TTST TATASTEEL TATLY MARUTI 500696 500477 GODREJCP AKLS ASHOKLEY

 
Godrej Consumer touches 52-week high; Macquarie maintains outperform

2018-08-20 moneycontrol
Shares of Godrej Consumer Products touched 52-week high of Rs 1,398.85, rising 4 percent intraday Monday as Macquarie maintained outperform rating on stock with target of Rs 1,465 per share.
GDRJY MS GODREJCP 532424

 
Godrej Consumer Products Limited - Updates

2018-08-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GDRJY GODREJCP 532424

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...